Literature DB >> 11905586

Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease.

U Lundstam1, J Herlitz, T Karlsson, T Lindén, O Wiklund.   

Abstract

OBJECTIVE: Our objective was to study prognostic factors for death in patients with coronary heart disease (CHD), focusing on serum lipids and lipoproteins. DESIGN AND
SUBJECTS: The study subjects were 964 patients with angina pectoris who underwent coronary angiography between 1985 and 1987. Follow-up, including survival and cause of death, was carried out in April 1998.
RESULTS: A total of 363 patients died. Increasing age, diabetes and low levels of HDL cholesterol and of apolipoprotein (apo) AI were associated with increased risk of total mortality and cardiac mortality. In men, low levels of LDL cholesterol and of apoB were associated with increased risk of death, but not of cardiac death only; high levels of lipoprotein(a) [Lp(a)] were not associated with increased risk. In women, however, there was a trend towards increased risk with increasing Lp(a) levels (P = 0.054); the smallest isoform of apo(a) was associated with a twofold increase in risk. In women, but not in men, risk decreased with increasing molecular weight of the apo(a) isoforms.
CONCLUSIONS: Amongst lipoprotein variables, low levels of HDL cholesterol and of apoAI and the presence of low-molecular weight isoforms of apo(a) are associated with increased risk of death in patients with CHD. Apo(a) isoforms and Lp(a) levels seem to be more important as risk factors amongst women. Low LDL cholesterol and apoB levels were associated with increased risk, but only in men. These findings demonstrate the importance of a gender-specific analysis of risk factors for CHD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11905586     DOI: 10.1046/j.1365-2796.2002.00937.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study.

Authors:  Stefania Lamon-Fava; Santica M Marcovina; John J Albers; Hal Kennedy; Carl Deluca; Charles C White; L Adrienne Cupples; Judith R McNamara; Leo J Seman; Vanina Bongard; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2011-04-07       Impact factor: 5.922

2.  The vascular implications of post-prandial lipoprotein metabolism.

Authors:  David R Sullivan; David S Celermajer; David G Le Couteur; Christopher W K Lam
Journal:  Clin Biochem Rev       Date:  2004-02

3.  Association of the HNF1A polymorphisms and serum lipid traits, the risk of coronary artery disease and ischemic stroke.

Authors:  Yi-Jiang Zhou; Rui-Xing Yin; Shao-Cai Hong; Qian Yang; Xiao-Li Cao; Wu-Xian Chen
Journal:  J Gene Med       Date:  2017-01       Impact factor: 4.565

Review 4.  Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-03-20

5.  Lipoprotein(a): an independent risk factor for ischemic heart disease that is dependent on triglycerides in subjects with type 2 diabetes mellitus.

Authors:  Ali Albahrani; Mohammed Alkindi; Eileen Marks; Said Alyahyaee; Alan Shenkin
Journal:  Lipids Health Dis       Date:  2007-10-02       Impact factor: 3.876

6.  Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects.

Authors:  Enzo Emanuele; Emmanouil Peros; Piercarlo Minoretti; Colomba Falcone; Angela D'Angelo; Lorenza Montagna; Diego Geroldi
Journal:  BMC Cardiovasc Disord       Date:  2003-12-12       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.